Post

New research · Ophthalmology
Journal of vitreoretinal diseases · 5d
Cohort studyJournal of vitreoretinal diseases · 2026

Real-World Safety of Intravitreal Complement Inhibitor Avacincaptad Pegol for Geographic Atrophy.

Alexander Shaer, Tadashi Yokoi, Eshani Ragam … Carl Regillo
Read paper
OphthalmologyCohort study

Avacincaptad pegol injections rarely caused eye inflammation or infection in real-world use.

Real-World Safety of Intravitreal Complement Inhibitor Avacincaptad Pegol for Geographic Atrophy.

Alexander Shaer … Carl Regillo
Journal of vitreoretinal diseases · 2026
Purpose

To evaluate the real-world ocular safety profile of intravitreal (intravitreal) avacincaptad pegol for geographic atrophy (geographic atrophy) secondary to age-related macular degeneration (AMD).

Methods

This retrospective study evaluated eyes with geographic atrophy secondary to AMD, including those with concurrent neovascular AMD (nAMD) treated with avacincaptad pegol.

n = 845 eyes
Results
0.02%
one in 5,000 injections caused eye swelling or infection - very low risk
n = 845 eyes
More results

Overall, 845 eyes of 590 patients (mean age, 81.8 ± 7.6 years; 71.9% female) received 5608 avacincaptad pegol injections.

Conversion occurred in 21 of 590 at-risk eyes (3.6%; 4.3% annualized) after a median of 3 injections (interquartile range, 3-5; range, 1-22).

More results

At baseline, nAMD was present in 25.1% of fellow eyes but accounted for 38.1% of conversions, reflecting a higher subgroup conversion rate of 5.4% (6.7% annualized).

Among 26 eyes with quiescent nAMD, reactivation occurred in 1 eye (3.8%) after a treatment-free interval of 7.5 years.

“
Conclusion

In this real-world cohort, a favorable safety profile was found with avacincaptad pegol, with low rates of inflammatory events, endophthalmitis, persistent ocular hypertension, and nAMD conversion, providing clinically relevant data to inform patient counseling and monitoring.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cross-sectional
44.1%
had too much homocysteine in the blood, a far larger share than in dry AMD or healthy eyes
Cohort Study
92.3%
most laser-treated eyes had a favorable eye-structure outcome
Cohort Study
56%
lost three or more lines on the eye-chart vision test
Cohort Study
50%
older patients were more likely to lose three or more lines of vision
Study
81%
trials where mask air leaks were detected blowing toward the eyes
Cohort Study
13.5%
Central retinal artery peak blood-flow speed was 13.5% lower in diabetic patients.
Study
379 +/- 156 microm
lower thickness in the central retina, checked with an eye scan
Case Report
9 of 10 eyes
eyes had better measured vision after treatment